


**BARNES & THORNBURG LLP**



11 South Meridian Street  
Indianapolis, Indiana 46204  
(317) 236-1313  
(317) 231-7433 Fax

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Group:</i>	3738	}	<u>Certificate Under 37 CFR 1.8(a)</u>
<i>Confirmation No.:</i>	9094	}	I hereby certify that this correspondence is being
<i>Application No.:</i>	10/044,031	}	deposited with the United States Postal Service with
<i>Invention:</i>	Purified Submucosa Graft Material	}	sufficient postage as first class mail in an envelope
<i>Applicant(s):</i>	Badylak et al.	}	addressed to Mail Stop RCE, Commissioner for
<i>Filed:</i>	January 11, 2002	}	Patents, P.O. Box 1450, Alexandria, VA 22313-1450
<i>Attorney Docket:</i>	3220-69262	}	
<i>Examiner:</i>	Paul B. Prebilio	}	
		}	on <u>July 5, 2007</u>
		}	<u>Rebecca Ball</u>
		}	(Signature)
		}	<u>Rebecca L. Ball</u>
		}	(Printed Name)

**INFORMATION DISCLOSURE STATEMENT**


Mail Stop RCE  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


This statement is filed in the application identified above pursuant to 37 C.F.R. § 1.56. No representation is intended that a complete search has been made of the prior art or that no better art references than those listed on the attached form PTO-1449 are available. Since this statement is being filed in accordance with 37 C.F.R. § 1.97(b)(4), Applicants submit that no fee is required. The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in §1.56(b).

The Commissioner is hereby authorized to charge any fees that might be due in connection with this Information Disclosure Statement to the Barnes & Thornburg Deposit Account No. 10-0435, with reference to our matter 3220-69262.

Respectfully submitted,  
BARNES & THORNBURG LLP

  
\_\_\_\_\_  
Rebecca L. Ball  
Attorney Reg. No. 46,535

Indianapolis, Indiana  
(317) 231-7511



Sheet 1 of 2

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
3220-69262

SERIAL No.  
10/044,031

APPLICANT(S): Badylak et al.

FILING DATE: January 11, 2002

GROUP: 3738

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	Dutkiewicz et al., "Levels of Bacteria, Fungi and Endotoxin in Stored Timber," <i>International Biodeterioration &amp; Biodegradation</i> , 30, 29-46 (1992).
AS	Barry N. Taylor, "Guide for the Use of the International Systems of Units (SI)," <i>National Institute of Standards and Technology</i> , Special Publication 811 (1995).
AT	"Bacterial Endotoxins/Pyrogens," Inspector's Technical Guide, <i>Dept. of Health, Education, and Welfare Public Health Service, Food and Drug Administration</i> , 40, (03-20-1985).
AU	Abstract of Yagoda et al., "Some effects of gram-negative bacterial endotoxin and its importance as a contaminator of biological preparations," <i>Acta Vet Scand.</i> , 31(2), 193-206 (1990).
AV	Abstract of Tsuji et al., "Recovery of endotoxin from human plasma by acid oxidative treatments as monitored by an automated microtiter plate-chromogenic substrate Limulus amebocyte lysate (LAL) assay method," <i>Prog Clin Biol Res.</i> , 231, 443-457 (1987).
AW	Abstract of Burd et al., "Endotoxin promotes synergistic lethality during concurrent Escherichia coli and Candida albicans infection," <i>J Surg Res.</i> , 52(6), 537-542 (June 1992).
AX	Zhang et al., "Differential Blocking of Coagulation-Activating Pathways of Limulus Amebocyte Lysate," <i>Journal of Clinical Microbiology</i> , 1537-1571 (June 1994).
AY	Casey et al., "Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome," <i>Annals of Internal Medicine</i> , Vol. 119 (Issue 8), 771-778 (October 15, 1993).
AZ	Abstract of Oettinger et al., "The clinical significance of prostaglandins and thromboxane as mediators of septic shock," <i>Journal of Molecular Medicine</i> , Vol. 65 (No. 2), 61-68 (January 1987).

Examiner

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 3220-69262		SERIAL No.: 10/044,031	
INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Badylak et al.		FILING DATE: January 11, 2002	
						GROUP: 3738	

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes    No
	BL						
	BM						
	BN						
	BO						
	BP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	BR	Sauter et al., "Etiology of Early Lifestage Diseases," Final Report 1985, Dept. of Microbiology and Immunology, Oregon Health Sciences University.
	BS	
	BT	
	BU	
	BV	
	BW	
	BX	
	BY	
	BZ	

Examiner	Date Considered
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449